[go: up one dir, main page]

MX2007000364A - Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16. - Google Patents

Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.

Info

Publication number
MX2007000364A
MX2007000364A MX2007000364A MX2007000364A MX2007000364A MX 2007000364 A MX2007000364 A MX 2007000364A MX 2007000364 A MX2007000364 A MX 2007000364A MX 2007000364 A MX2007000364 A MX 2007000364A MX 2007000364 A MX2007000364 A MX 2007000364A
Authority
MX
Mexico
Prior art keywords
wnt16
methods
inhibit
agents
treating cancer
Prior art date
Application number
MX2007000364A
Other languages
English (en)
Inventor
Liang You
Biao He
Zhidong Xu
David M Jablons
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2007000364A publication Critical patent/MX2007000364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Esta invencion se relaciona a metodos para inhibir el crecimiento de celulas, en particular celulas de cancer que sobreexpresan la proteina Wnt16. Los metodos comprenden poner en contacto la celula con un agente que enlaza a mRNA de Wnt16 o la proteina Wnt16, interfiere con la senalizacion de Wnt16 o inhibe el enlace de la proteina Wnt16 a otra proteina, tal como un receptor Frizzled.
MX2007000364A 2004-07-09 2005-07-11 Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16. MX2007000364A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58656404P 2004-07-09 2004-07-09
US64570905P 2005-01-20 2005-01-20
PCT/US2005/024759 WO2006017318A2 (en) 2004-07-09 2005-07-11 Methods for treating cancer using agents that inhibit wnt16 signaling

Publications (1)

Publication Number Publication Date
MX2007000364A true MX2007000364A (es) 2007-06-25

Family

ID=35839795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000364A MX2007000364A (es) 2004-07-09 2005-07-11 Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.

Country Status (10)

Country Link
US (1) US20080267951A1 (es)
EP (1) EP1771207A4 (es)
JP (1) JP2008505933A (es)
CN (1) CN101687005A (es)
AU (1) AU2005271763A1 (es)
CA (1) CA2571955A1 (es)
IL (1) IL180295A0 (es)
MX (1) MX2007000364A (es)
RU (1) RU2007104925A (es)
WO (1) WO2006017318A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
RU2636000C2 (ru) * 2012-02-28 2017-11-17 Новартис Аг ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
US9759725B2 (en) * 2012-08-02 2017-09-12 Fred Hutchinson Cancer Research Center Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
CN115991769A (zh) * 2015-03-27 2023-04-21 中国科学院上海营养与健康研究所 特异性靶向wnt16b的抗体在制备抗肿瘤药物中的应用
MX2019011749A (es) * 2017-03-28 2020-01-23 Dicerna Pharmaceuticals Inc Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607915B1 (en) * 1999-09-30 2003-08-19 Isis Pharmaceuticals, Inc. Antisense inhibition of E2A-Pbx1 expression
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
KR100464864B1 (ko) * 2002-04-25 2005-01-06 엘지.필립스 엘시디 주식회사 유기전계발광 소자 및 그의 제조방법
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE

Also Published As

Publication number Publication date
CA2571955A1 (en) 2006-02-16
EP1771207A4 (en) 2009-05-27
WO2006017318A3 (en) 2007-09-27
EP1771207A2 (en) 2007-04-11
JP2008505933A (ja) 2008-02-28
AU2005271763A1 (en) 2006-02-16
IL180295A0 (en) 2007-06-03
CN101687005A (zh) 2010-03-31
US20080267951A1 (en) 2008-10-30
RU2007104925A (ru) 2008-08-20
WO2006017318A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2005116236A3 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
WO2004032838A3 (en) Methods for treating cancer by inhibiting wnt signaling
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
EA201001223A1 (ru) Стабилизированные белковые композиции
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
ATE514434T1 (de) Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
TW200603828A (en) Treatment of disorders
WO2006073443A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
TW200745159A (en) IL-6 binding proteins
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
MX2007000364A (es) Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2008033887A8 (en) Methods for treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal